Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Normethermic Intraperitoneal Chemotherapy with carboplatin.
- Who it may be relevant to
- Registry conditions: Ovarian Cancer. Basic parameters: from 70 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Normothermic Intraperitoneal Chemotherapy (NIPEC) With Carboplatin Following Cytoreductive Surgery in Elderly and Frail Ovarian Cancer Patients: a Feasibility Study.
Overview
The purpose of this feasibility study is to investigate whether NIPEC with carboplatin after surgery is safe for the elderly and frail women with advanced ovarian cancer. To achieve this, women with advanced ovarian cancer who receive surgery followed by NIPEC will be closely monitored in the period after treatment. We will assess complications, side effects, recovery after surgery and NIPEC, and whether standard chemotherapy can be started on time and completed as planned. In addition, participants will be followed for six months using questionnaires and interviews to evaluate patient-reported outcomes, including quality of life. In the more technical assessment of NIPEC, carboplatin tissue pharmacokinetics and inflammatory responses during and after NIPEC will be analysed using microdialysis and histology.
Interventions
- Drug Normethermic Intraperitoneal Chemotherapy with carboplatin
Normothermic Intraperitoneal Chemotherapy is being performed intraoperatively with carboplatin 800mg/m\^2 for 90 min intraperitoneal circulation at normal body temperature 36.5-37.5℃.
Primary outcome measures
- Proportion of Participants with Treatment-Related Adverse Events and Adverse Reactions [Time frame: The day that adjuvant chemotherapy starts (up to 4-6 weeks).]
Secondary outcome measures (12)
- Length of hospital stay [Time frame: The day of hospital discharge (up to 14 days).]
- Proportion of reoperations [Time frame: The day that adjuvant chemotherapy starts (up to 4-6 weeks).]
- Proportion of readmissions. [Time frame: The day that adjuvant chemotherapy starts (up to 4-6 weeks).]
- Time from surgery to the first dose of adjuvant systemic chemotherapy. [Time frame: The day that adjuvant chemotherapy starts (up to 4-6 weeks).]
- Completion of adjuvant chemotherapy. [Time frame: At second follow up (3 months).]
- Patients' willingness to participate. [Time frame: At study completion (at 6 months)]
- Patient reported adverse events [Time frame: At first follow up (up to 6 weeks).]
- Change in health-related quality of life using EORCT-questionnaires [Time frame: Baseline, follow-up 1 (up to 6 weeks), follow-up 2 (3 months) and follow-up 3 (6 months).]
- Carboplatin AUC in peritoneum parietale [Time frame: 30, 60, 90, 120, 150, 180, 210, 240, 300, 360 min. post-dose]
- Carboplatin Cmax in peritoneum parietale [Time frame: Up to 360 min. post-dose]
- Carboplatin Tmax in peritoneum parietale [Time frame: Up to 360 min. post-dose]
- Carboplatin T½ in peritoneum parietale [Time frame: Up to 360 min. post-dose]
Eligibility criteria
Inclusion criteria
- Signed informed consent.
- Patient capability of giving informed consent.
- Age ≥ 70 years.
- Women diagnosed with epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer FIGO stage III-IV with planned interval cytoreductive surgery. Stage IV patients will only be included if they have resectable metastases within the abdominal cavity and/or abdominal wall or if they have complete remission of extra-abdominal metastases after three series of neoadjuvant chemotherapy.
- Performance status 1-3.
- American Society of Anaesthesiologists (ASA) scores I-III.
- Normal preoperative kidney, liver and bone marrow function (according to the CTCAE v.5.0): Normal kidney function definition: eGFR or GFR ≥ 60 ml/min. Normal liver function: ALAT and/OR ASAT ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 ×ULN. Normal bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 75 × 10⁹/L; Haemoglobin level ≥ 6 mmol/L;
- Completeness of cytoreduction to less than 2.5 mm.
- Demographically belonging to Region of Southern Denmark.
Exclusion criteria
- Progression of disease during NACT.
- Intrabdominal metastases not resectable upon NACT.
- Former history of breast cancer or other malignancies within 5 years before inclusion, except from non-melanomatous skin cancer.
- Contradictions to receive carboplatin according to the SmPC (the medical oncologist makes the decision): Drug allergy (active drug or components); Severe myelosuppression; Severe kidney deficiency (creatinin clearance ≤ 30 ml/min); Bleeding tumours; Concurrent usage of vaccination against yellow fever; Severe allergic reaction to other platinum compounds in the medical history.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Denmark · 1 center
- Odense University Hospital — Odense
Identifiers
NCT: NCT07733505 · 26/12528 · 2025-522269-30-00